BioCryst製藥 BCRX 深 滬
等待開盤 01-28 09:30:00 美东时间
6.76
-0.100
-1.46%
華盛通- 最 高6.94
- 今 開6.81
- 成交量 470.95万股
- 最 低 6.5946
- 昨 收 6.86
- 總市值 14.26亿
- 52周最高 11.31
- 市盈率 靜 --
- 換手率 2.23%
- 52周最低 6.00
- 委 比 -15.59%
- 總股本 2.11亿
- 歷史最高 19.99
- 量 比 0.92
- 振 幅 5.03%
- 歷史最低 1.08
- 每 手 1
- 風險率 1.13%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多财报速睇 | BioCryst制药 2025财年Q3营收0.01亿美元，去年同期无营收；归母净利润亏损0.32亿美元，同比亏损扩大29.0%
华盛资讯1月24日讯，BioCryst制药公布2025财年Q3业绩，公司Q3营收0.01亿美元，去年同期无营收，归母净利润亏损0.32亿美元，同比亏损扩大29.0%。
01-24 10:04
BRIEF-Astria Stockholders Vote To Approve Acquisition By Biocryst
BRIEF-Astria Stockholders Vote To Approve Acquisition By Biocryst Jan 21 (Reuters) - Astria Therapeutics Inc ATXS.O : ASTRIA STOCKHOLDERS VOTE TO APPROVE ACQUISITION BY BIOCRYST Source text: ID:nBw7DYHBTa Further company coverage: ATXS.O (( Reuters.Briefs@thomsonreuters.com ;))
01-22 05:42
BioCryst Pharma Sees FY2026 Sales $635.000M-$660.000M vs $657.200M Est
BioCryst Pharma (NASDAQ:BCRX) sees FY2026 sales of $635.000 million-$660.000 million vs $657.200 million analyst estimate.
01-12 20:26
美股大行评级 | 潜在涨幅113%！麦格理首予小马智行“跑赢大市"评级目标价29美元；Roth Capital下调好市多至"卖出"，目标价从906美元降至769美元
今日重点评级关注：HC Wainwright & Co.：维持BioCryst Pharma"买入"评级，目标价从30美元升至32美元；TD Cowen：上调Milestone Pharmaceuticals评级至"买入"，目标价8美元
2025-12-16 09:36
FDA Approves BioCryst's NDA For Use Of Oral Pellet Formulation Of Once-Daily ORLADEYO For Prophylactic Therapy In Pediatric Patients With Hereditary Angioedema Aged 2 To <12 Years
–ORLADEYO now first and only targeted oral prophylactic therapy for patients with HAE aged 2 and older–-Oral pellet formulation provides child-friendly method of administration-–Showed early and sustained reductions in
2025-12-12 20:02
美股大行评级 | 最高325美元！10家机构集体上调AMD目标价；Pinterest遭14家大行下调目标价；大行对优步目标价分歧大，5家下调5家上调
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从3美元升至9美元；HC Wainwright & Co.：上调CervoMed评级至"买入"，目标价从11美元升至25美元
2025-11-06 09:55
美股大行评级 | 最高255美元！9家大行集体上调Palantir目标价；Axsome、Exact、Fabrinet、ZoomInfo、爱德士、MongoDB、安森美半导体等也获多家大行上调目标价
今日重点评级关注：瑞银：维持Syndax Pharmaceuticals"买入"评级，目标价从35美元升至38美元；HC Wainwright & Co.：维持Benitec Biopharma"买入"评级，目标价从28美元升至35美元
2025-11-05 10:35
Needham Maintains Buy on BioCryst Pharma, Lowers Price Target to $18
Needham analyst Serge Belanger maintains BioCryst Pharma (NASDAQ:BCRX) with a Buy and lowers the price target from $20 to $18.
2025-11-04 18:41
BioCryst Pharma Raises FY2025 Sales Guidance from $580.000M-$600.000M to $590.000M-$600.000M vs $625.558M Est
BioCryst Pharma (NASDAQ:BCRX) raises FY2025 sales outlook from $580.000 million-$600.000 million to $590.000 million-$600.000 million vs $625.558 million estimate.
2025-11-03 20:01
BioCryst Pharma Q3 Adj. EPS $0.16 Beats $0.04 Estimate, Sales $159.395M Miss $162.974M Estimate
BioCryst Pharma (NASDAQ:BCRX) reported quarterly earnings of $0.16 per share which beat the analyst consensus estimate of $0.04 by 357.14 percent. This is a 328.57 percent increase over losses of $(0.07) per share from
2025-11-03 20:00
